Canakinumab doesn't prevent prediabetes from progressing to diabetes

March 12, 2018, American College of Cardiology

The anti-inflammatory drug canakinumab had no effect on rates of newly diagnosed diabetes in people who had prediabetes (elevated blood sugar levels at risk of developing into diabetes), according to research presented at the American College of Cardiology's 67th Annual Scientific Session.

The research is a key secondary endpoint from the CANTOS study, a large trial that last year reported canakinumab significantly reduced major adverse cardiovascular outcomes (the trial's primary endpoint) in patients with a history of heart attack and elevations in the inflammatory marker high-sensitivity C-reactive protein (hsCRP). Since diabetes is thought to be related to inflammatory processes like those involved in heart disease, researchers hypothesized that the drug may help slow or prevent the progression from prediabetes to diabetes.

Patients with prediabetes at the start of the study initially showed a reduction in (as indicated by a drop from 5.8 to 5.6 in median hemoglobin A1c, a measure of average blood sugar over the previous three months) after six months of taking canakinumab. However, this effect disappeared after about nine months and these patients were ultimately diagnosed with diabetes at a rate comparable to those who received a placebo.

"The results were surprising, because we demonstrated there was an effect on that didn't translate into a reduced rate of Type 2 diabetes diagnosis," said Brendan Everett, MD, a cardiologist at Brigham and Women's Hospital, assistant professor of medicine at Harvard Medical School and the study's lead author. "It suggests that alternative inflammatory pathways may be more critical to the development of diabetes than inhibition of interleukin-1 beta, which was the specific mechanism we tested in this study."

Canakinumab is designed to disable interleukin-1 beta, a protein that plays a role in inflammation. The drug is approved for several autoimmune disorders and is being investigated for the management of .

The CANTOS trial enrolled more than 10,000 patients. Of those, about 4,000 had diabetes at the start of the trial and 1,000 had normal . The new analysis focuses on the remaining 4,960 patients, who had prediabetes at the start of the trial. In general, people with prediabetes are likely to progress to diabetes unless they adopt substantial lifestyle changes such as losing weight and getting more exercise.

Participants were randomly assigned to receive either a placebo or canakinumab in one of three dosing levels (50, 150 or 300 milligrams per dose). Patients were given injections of the drug (or placebo) every three months for a median of more than 3.5 years. After the study ended and all participants stopped receiving injections, researchers continued to follow those who had prediabetes at baseline for an additional six months.

While there was no effect on diabetes progression, patients with prediabetes showed significant reductions in two major markers of inflammation, hsCRP and interleukin-6. They derived the same benefits from canakinumab as other patients in the study in terms of cardiovascular outcomes, including reduced rates of heart attack, stroke and death from cardiovascular causes.

"Canakinumab is an effective therapy to prevent major cardiovascular events in patients with and without diabetes," Everett said. "It seems to prevent cardiovascular events without increasing the development of Type 2 diabetes among patients who are at risk for the disorder."

In a secondary analysis, the investigators examined the effect of canakinumab on blood glucose in patients with diabetes at the start of the study. In these patients, canakinumab led to similar changes in glucose levels as was seen in patients with prediabetes. However, patients assigned to take canakinumab still required a similar number of diabetes medications, including insulin, as the taking the placebo. One potential area for future research could be to investigate whether canakinumab may contribute to glucose management among people who already have Type 2 .

Explore further: Canakinumab reduces risk of cardiovascular events in populations with unmet clinical need

Related Stories

Canakinumab reduces risk of cardiovascular events in populations with unmet clinical need

March 12, 2018
Two new analyses of data from more than 10,000 heart attack survivors worldwide were presented by investigators from Brigham and Women's Hospital at the 2018 American College of Cardiology meeting. Paul Ridker, MD, director ...

Response after single treatment with canakinumab predicts which patients will benefit most

November 13, 2017
A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American Heart Association Scientific ...

Study finds prediabetes patients at heightened risk for cardiovascular and chronic kidney diseases

March 1, 2018
Researchers at the Emory Rollins School of Public Health and U.S. Centers for Disease Control and Prevention have found that high proportions of patients with prediabetes are at substantial risk for cardiovascular disease ...

Worse prognosis for prediabetes defined by HbA1c

February 22, 2018
(HealthDay)—Prediabetes defined by hemoglobin A1c (HbA1c) is associated with worse prognosis than definition by fasting plasma glucose (FPG) or two-hour plasma glucose (2hPG), according to a study published online Feb. ...

Anti-inflammatory therapy cuts risk of lung cancer

August 28, 2017
In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique opportunity: to explore the ...

Inflammation reduction could cut risk of heart attack, stroke

August 28, 2017
A significant reduction in risk of recurrent heart attacks, strokes, and cardiovascular death was found among people who received a targeted anti-inflammatory drug that lowered inflammation but had no effects on cholesterol, ...

Recommended for you

Consuming low-calorie sweeteners may predispose overweight individuals to diabetes

March 18, 2018
Consumption of low-calorie sweeteners could promote metabolic syndrome and predispose people to prediabetes and diabetes, particularly in individuals with obesity, a new study on human fat-derived stem cells and fat samples ...

Are high blood glucose levels an effect rather than the cause of diabetes?

March 15, 2018
Insulin resistance and elevated blood glucose levels are considered to be the cause of type 2 diabetes. However, scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now provided ...

Smoking linked with higher risk of type 2 diabetes

March 15, 2018
The prevalence of diabetes has increased almost 10-fold in China since the early 1980s, with one in 10 adults in China now affected by diabetes. Although adiposity is the major modifiable risk factor for diabetes, other research ...

Social support and machine learning are at the core of a student-developed app for people with diabetes

March 14, 2018
Diabetes is the seventh leading cause of death in the U.S., and nearly 10 percent of the population suffers from this chronic disease, according to the Centers for Disease Control and Prevention.

Toxic proteins and type 2 diabetes

March 9, 2018
Nearly a half-billion people worldwide live with type 2 diabetes. Yet despite the disease's sizeable and increasing impact, its precise causes remain murky. Current scientific thinking points to two key processes: insulin ...

Fiber-fermenting bacteria improve health of type 2 diabetes patients

March 8, 2018
The fight against type 2 diabetes may soon improve thanks to a pioneering high-fiber diet study led by a Rutgers University-New Brunswick professor.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.